Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Neothetics ($NEOT) shot up in its previous trading session and ended 19.79% higher at $1.15. The main impetus for the stock came from the news that it has started a Phase 2 clinical trial, LIPO-202-CL-31, evaluating lead product candidate LIPO-202 for the reduction of submental subcutaneous fat (fat under the chin). The study will involve 150 subjects.
The company stock lost over 29% in the past one year. It had reported its third quarter loss at $2.4 million or $0.17 per share, down from $1.26 per share net loss it had reported for the corresponding quarter of the previous year.

Myriad Genetics ($MYGN) faces the risk of its rheumatoid arthritis (RA) test Vectra DA may be excluded from coverage under Medicare program. The company told Streetinsider that it is disappointed that the MolDx program published a draft non-coverage decision for the test. Myriad stated that it strongly disagrees with the conclusions.
The decision has been based on data from the recently published AMPLE study. The company said that the study had severe shortcomings and limitations. It further stated that over 20 studies covering more than 3,000 patients have demonstrated the efficacy of the test.
The decision is not final yet. Myriad stock had a rough year as it lost over 60% of its value this year.

 

• Progenics ($PGNX) announced that its independent monitoring committee has completed its review of an interim analysis of the ongoing Phase 3 trial of the company's PSMA-targeted SPECT/CT imaging agent candidate, 99mTc-MIP-1404. The committee has recommended the trial to be continued.
• Impax Laboratories ($IPXL) announced the launch of its generic version of Teva's ($TEVA) Kadian (morphine sulfate) Extended Release Capsules, USP CII 20, 30, 50, 80 and 100 mg in the U.S.

• Alcon ($NVS) announced receiving approval from the Food and Drug Administration for AcrySof IQ ReSTRO +3.0D Multifocal Toric Intraocular Lens, designed to address presbyopia (age-related farsightedness) and pre-existing corneal astigmatism at the time of cataract surgery in adult patients.
• Avinger ($AVGR) announced receiving 501(K) clearance from the FDA for its Lightbox L250 imaging console. According to the company, the product offers elaborate measurement of vessels, enhancing visualization inside the vessel before, during and after Pantheris Lumivascular atherectomy procedure for the treatment of peripheral artery disease.
• NeuroDerm ($NDRM) announced completing the enrollment and treatment in its 38-subject Phase 2 clinical trial (trial 006) assessing ND0612H in patients suffering from advanced Parkinson's disease (PD).

 

• Ligand Pharmaceuticals ($LGND) signed entering into a global license and supply agreement with Novartis ($NVS) for the purpose of developing and commercializing a Captisol-enabled oral liquid formulation of melanoma med Mekinist (trametinib).
• Strongbridge Biopharma ($SBBP) announced that the Company has acquired the U.S. rights to KEVEYIS (dichlorphenamide) from a subsidiary of Taro Pharmaceutical Industries ($TARO).

• Cardiome Pharma (CRME) initiated with Outperform rating from Leerink Swann and the price target is set at $4.75.
• Merus NV ($MRUS) receives rating upgrade from Neutral to Buy from Citigroup. Its price target is also raised from $19 to $26 apiece.

Gainers (% price change) Last Trade Change Mkt Cap
Synergy Pharmaceuticals
SGYP (NASDAQ)
5.77 +1.03 (21.73%) 1.04B
China Cord Blood Corp
CO (NYSE)
6.34 +0.99 (18.50%) 465.77M
Amicus Therapeutics, Inc.
FOLD (NASDAQ)
4.99 +0.46 (10.15%) 688.92M
NewLink Genetics Corp
NLNK (NASDAQ)
10.99 +0.98 (9.79%) 314.53M
Achillion Pharmaceuticals
ACHN (NASDAQ)
4.38 +0.39 (9.77%) 578.37M
Losers (% price change)
Myriad Genetics, Inc.
MYGN (NASDAQ)
16.88 -0.75 (-4.25%) 1.11B
Accuray Incorporated
ARAY (NASDAQ)
4.60 -0.15 (-3.16%) 375.79M
STAAR Surgical Company
STAA (NASDAQ)
11.20 -0.25 (-2.18%) 462.91M
Bovie Medical Corporation
BVX (NYSE)
3.80 -0.04 (-1.04%) 108.28M
Sinovac Biotech Ltd.
SVA (NASDAQ)
5.79 -0.05 (-0.86%) 346.71M
Most Actives (dollar volume)
Merck & Co., Inc.
MRK (NYSE)
59.56 -0.02 (-0.03%) 164.63B
Gilead Sciences, Inc.
GILD (NASDAQ)
73.64 +0.34 (0.46%) 96.15B
Humana Inc
HUM (NYSE)
205.53 +2.60 (1.28%) 31.12B
Pfizer Inc.
PFE (NYSE)
32.48 +0.14 (0.43%) 194.04B
Johnson & Johnson
JNJ (NYSE)
115.96 +0.52 (0.45%) 315.83B